Clinical Predictors and Prediction Models for RFVIII-Fc Half Life in Real-World People with Severe Hemophilia A

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Mar 29

PMID 36983209

Authors

Chia-Yau Chang

Shyh-Shin Chiou

Te-Fu Weng

Pei-Chin Lin

Shiue-Wei Lai

Chen-Hua Tsai

Yen-Lin Liu

Jung-Tzu Ku

Yu-Mei Liao

Jia-Ruey Tsai

Shu-Hsia Hu

Chao-Neng Cheng

Yeu-Chin Chen

Affiliations

Soon will be listed here.

Abstract

The half life of recombinant factor VIII-Fc (rFVIII-Fc) for people with hemophilia A (PwHA) varies greatly. Understanding the factors influencing the variation and assessment of rFVIII-Fc half life is important for personalized treatment. Eighty-five severe-type PwHA with rFVIII-Fc treatment receiving an evaluation of half life by the Web-Accessible Population Pharmacokinetic (PK) Service-Hemophilia during 2019-2021 were retrospectively enrolled. The 50-patient PK profiles before 2021 were used for analysis and developing prediction models of half life, and the 35-patient PK profiles in 2021 were used for external validation. The patients in the development cohort were aged 8-64, with a median rFVIII-Fc half life of 20.75 h (range, 8.25-41.5 h). By multivariate linear regression analysis, we found two, four, and five predictors of rFVIII-Fc half life for the blood groups non-O, O patients, and overall patients, respectively, including baseline VWF:Ag, BMI, VWF:activity/VWF:Ag ratio, body weight, O blood group, inhibitor history, HCV infection, and hematocrit. The three prediction equations of rFVIII-Fc half life (T) were respectively developed as T for non-O group patients = -0.81 + 0.63 × (BMI, kg/m) + 6.07 × (baseline VWF:Ag, IU/mL), T for O group patients = -0.68 + 13.30 × (baseline VWF:Ag, IU/mL) + 0.27 × (BW, kg) - 1.17 × (BMI, kg/m) + 16.02 × (VWF:activity/VWF:Ag ratio), and T for overall patients = -1.76 + 7.24 × (baseline VWF:Ag, IU/mL) - 3.84 × (Inhibitor history) + 2.99 × (HCV infection) - 2.83 × (O blood group) + 0.30 × (Hct, %), which explained 51.97%, 75.17%, and 66.38% of the half life variability, respectively. For external validation, there was a significant correlation between the predicted and observed half lives in the validation cohort. The median half life deviation was +1.53 h, +1.28 h, and +1.79 h for the equations of non-O group, O group, and overall group patients, respectively. In total, eight predictors influencing rFVIII-Fc half life were identified. Prediction equations of rFVIII-Fc half life were developed for the non-O and O blood groups and overall PwHA with a good degree of external validation. The equations could be applied to patients aged 8-64 without the need for PK blood sampling and clinically valuable for personalized therapy.

References

Kepa S, Horvath B, Reitter-Pfoertner S, Schemper M, Quehenberger P, Grundbichler M . Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. Haemophilia. 2015; 21(3):343-350. DOI: 10.1111/hae.12592. View

Manco-Johnson M, Abshire T, Shapiro A, Riske B, Hacker M, Kilcoyne R . Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-44. DOI: 10.1056/NEJMoa067659. View

van Leeuwen F, van Bergen E, Timmer M, van Vulpen L, Schutgens R, de Jong P . Magnetic resonance imaging evidence for subclinical joint bleeding in a Dutch population of people with severe hemophilia on prophylaxis. J Thromb Haemost. 2023; 21(5):1156-1163. DOI: 10.1016/j.jtha.2023.01.035. View

De la Corte-Rodriguez H, Rodriguez-Merchan E, Alvarez-Roman M, Martin-Salces M, Martinoli C, Jimenez-Yuste V . The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia. Expert Rev Hematol. 2018; 11(3):253-261. DOI: 10.1080/17474086.2018.1435269. View

Lalezari S, Martinowitz U, Windyga J, Enriquez M, Delesen H, Schwartz L . Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia. 2013; 20(1):e15-22. PMC: 4233978. DOI: 10.1111/hae.12294. View

Shipe M, Deppen S, Farjah F, Grogan E . Developing prediction models for clinical use using logistic regression: an overview. J Thorac Dis. 2019; 11(Suppl 4):S574-S584. PMC: 6465431. DOI: 10.21037/jtd.2019.01.25. View

van Dijk K, van der Bom J, Lenting P, de Groot P, Mauser-Bunschoten E, Roosendaal G . Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica. 2005; 90(4):494-8. View

Versloot O, Iserman E, Chelle P, Germini F, Edginton A, Schutgens R . Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. J Thromb Haemost. 2021; 19(8):1896-1906. PMC: 8361743. DOI: 10.1111/jth.15395. View

Hazendonk H, Lock J, Mathot R, Meijer K, Peters M, Laros-van Gorkom B . Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. J Thromb Haemost. 2015; 14(3):468-78. DOI: 10.1111/jth.13242. View

10.

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J . Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015; 13(6):967-77. DOI: 10.1111/jth.12911. View

11.

Altman D, Vergouwe Y, Royston P, Moons K . Prognosis and prognostic research: validating a prognostic model. BMJ. 2009; 338:b605. DOI: 10.1136/bmj.b605. View

12.

McEneny-King A, Iorio A, Foster G, Edginton A . The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opin Drug Metab Toxicol. 2016; 12(11):1313-1321. DOI: 10.1080/17425255.2016.1214711. View

13.

Konkle B . Von Willebrand factor and aging. Semin Thromb Hemost. 2014; 40(6):640-4. DOI: 10.1055/s-0034-1389079. View

14.

Schrijvers L, Schuurmans M, Fischer K . Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals. Haemophilia. 2016; 22(4):499-506. DOI: 10.1111/hae.12904. View

15.

Fijnvandraat K, Peters M, Ten Cate J . Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol. 1995; 91(2):474-6. DOI: 10.1111/j.1365-2141.1995.tb05325.x. View

16.

Gringeri A, Wolfsegger M, Steinitz K, Reininger A . Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling. Haemophilia. 2015; 21(3):300-306. DOI: 10.1111/hae.12605. View

17.

Leiderman K, Sindi S, Monroe D, Fogelson A, Neeves K . The Art and Science of Building a Computational Model to Understand Hemostasis. Semin Thromb Hemost. 2021; 47(2):129-138. PMC: 7920145. DOI: 10.1055/s-0041-1722861. View

18.

Fischer K, van der Bom J, Mauser-Bunschoten E, Roosendaal G, Prejs R, de Kleijn P . The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood. 2002; 99(7):2337-41. DOI: 10.1182/blood.v99.7.2337. View

19.

Lissitchkov T, Rusen L, Georgiev P, Windyga J, Klamroth R, Gercheva L . PK-guided personalized prophylaxis with Nuwiq (human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia. 2017; 23(5):697-704. DOI: 10.1111/hae.13251. View

20.

Chang C, Lai S, Cheng M, Ku J, Hu S, Liu Y . Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy. Int J Hematol. 2022; 117(3):378-387. DOI: 10.1007/s12185-022-03503-9. View